3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
36
Neoplasms
32
Prostatic Neoplasms
26
Colorectal Neoplasms
25
Lung Neoplasms
21
Carcinoma, Non-Small-Cell Lung
16
Hematologic Neoplasms
13
Neoplasm Metastasis
10
Pancreatic Neoplasms
9
Ovarian Neoplasms
8
Multiple Myeloma
8
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Hematopoietic and Lymphatic System Neoplasm
7
Stomach Neoplasms
6
Carcinoma, Renal Cell
6
Anatomic Stage I Breast Cancer AJCC v8
6
Uterine Cervical Neoplasms
5
Sarcoma
5
Glioma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Mouth Neoplasms
4
Motor Activity
4
Melanoma
4
Leukemia, Myeloid, Acute
4
Hematopoietic and Lymphoid System Neoplasm
4
Head and Neck Carcinoma
4
Gastrointestinal Neoplasms
4
Interventions
Cyclophosphamide
6
Vincristine
3
Temozolomide
3
Radiotherapy
3
Cisplatin
3
Automobiles
3
fludarabine
2
Etoposide
2
Eflornithine
2
Carboplatin
2
omburtamab I-131
1
ibrutinib
1
gallium Ga 68 dotatate
1
etoposide phosphate
1
belzutifan
1
Zoledronic Acid
1
Thiotepa
1
Tamoxifen
1
Standard of Care
1
Radiotherapy, Image-Guided
1
Pemetrexed
1
ONC206
1
Nivolumab
1
Mesna
1
Maintenance Chemotherapy
1
Lomustine
1
Isotretinoin
1
Induction Chemotherapy
1
Hydrocortisone
1
HhAntag691
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
Standard of Care
×
1 year
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled